AltMountain

Monashee Investment Management, LLC

Boston, MA · CRD 163148
Hedge fund manager

Monashee Investment Management, LLC is an SEC-registered investment adviser based in Boston, MA that reports managing 1 hedge fund on Form ADV. It reports $1.9 billion in regulatory assets under management. Its private funds, of all types, hold $139.2 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +15.9% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +66.2% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$1.9 billionForm ADV Item 5.F
Gross assets of private funds
$139.2 millionAll private fund types, Form ADV
Hedge funds managed
11 private funds in total
Employees
13Form ADV Item 5.A
Registration
SEC-registered adviserCRD 163148
Latest Form ADV
02/27/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+15.9%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+66.2%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$54.2 million20 positions, 2026-06-30
$100$133$166Q3 2024Q1 2025Q3 2025Q1 202613F est. $166S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+19.5%+14.8%
Q1 2026-3.0%-4.6%
Q4 2025-1.2%+2.4%
Q3 2025+23.5%+7.8%
Q2 2025+12.0%+10.4%
Q1 2025-1.5%-4.5%
Q4 2024-0.5%+2.1%
Q3 2024+7.1%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 16 share positions ($33,404,308) reported by Monashee Investment Management LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 6, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Axon Enterprise Inc14.80%
  • Immix Biopharma Inc14.02%
  • Sysco Corp12.84%
  • Newcleo PLC9.40%
  • Adt Inc Del9.10%
  • Solid Biosciences Inc8.87%
  • Enbridge Inc6.96%
  • Viking Therapeutics Inc4.60%
  • Blossomhill Therapeutics Inc4.46%
  • Electra Therapeutics Inc3.37%
StockValue% of 13F portfolioSharesShares vs prior quarter
Axon Enterprise Inc$4,943,55014.80%5,000,000New
Immix Biopharma Inc$4,682,25014.02%450,000New
Sysco Corp$4,287,80012.84%55,000New
Newcleo PLC$3,140,0009.40%400,000New
Adt Inc Del$3,040,0009.10%500,000-16.67%
Solid Biosciences Inc$2,964,3008.87%410,000-18.00%
Enbridge Inc$2,324,5006.96%50,000New
Viking Therapeutics Inc$1,537,7254.60%1,500,000New
Blossomhill Therapeutics Inc$1,491,2004.46%80,000New
Electra Therapeutics Inc$1,125,0003.37%100,000New
Yarrow Bioscience Inc$900,8002.70%40,000New
Imagenebio Inc$811,0912.43%177,094-7.93%
Aveanna Healthcare Hldgs Inc$620,5001.86%50,000New
Pyxis Oncology Inc$534,2921.60%229,310New
Orion180 Ins Group Inc$530,2001.59%55,000New
Hagerty Inc$471,1001.41%35,000New

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 13 new positions, 17 sold out, 0 increased, 3 reduced and 0 unchanged.

Number of positions (a count, not dollars)

  • New positions13
  • Increased0
  • Unchanged0
  • Reduced3
  • Sold out17

New positions

StockValueShares
Axon Enterprise Inc$4,943,5505,000,000
Immix Biopharma Inc$4,682,250450,000
Sysco Corp$4,287,80055,000
Newcleo PLC$3,140,000400,000
Enbridge Inc$2,324,50050,000
Viking Therapeutics Inc$1,537,7251,500,000
Blossomhill Therapeutics Inc$1,491,20080,000
Electra Therapeutics Inc$1,125,000100,000
Yarrow Bioscience Inc$900,80040,000
Aveanna Healthcare Hldgs Inc$620,50050,000
Pyxis Oncology Inc$534,292229,310
Orion180 Ins Group Inc$530,20055,000
Hagerty Inc$471,10035,000

Sold out

StockValue at Jun 30, 2026Shares held then
Alphabet Inc$5,089,000100,000
Alphabet Inc$5,030,000100,000
Digital Rlty TR Inc$4,489,50025,000
Spyre Therapeutics Inc$4,439,00050,000
Tango Therapeutics Inc$3,126,000100,000
Super Micro Computer Inc$2,598,00050,000
Legend Biotech Corp$2,465,91985,385
Alphabet Inc$2,144,2206,000
Alphabet Inc$2,119,9806,000
Uniqure NV$2,072,70045,000
Innio NV$1,884,55847,650
Acadia Rlty TR$1,785,40085,385
Pattern Group Inc$1,613,14264,039
Moonlake Immunotherapeutics$1,460,25075,000
Whitehawk Minerals Corp$1,425,27451,232
Taysha Gene Therapies Inc$1,362,000200,000
Kardigan Inc$1,018,22842,693

Largest reductions

StockChange in sharesChangeValue nowShares now
Solid Biosciences Inc-90,000-18.00%$2,964,300410,000
Adt Inc Del-100,000-16.67%$3,040,000500,000
Imagenebio Inc-15,250-7.93%$811,091177,094

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌‌​​​​​​​​​​⁠